Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Oncothyreon Inc. (ONTY) Report Updated: Nov 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

Oncothyreon Inc. (ONTY)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: EBS, EGRX, ZIOP, NBIX

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: B down downgrade
Last Week: A same no change
Two Weeks Ago: A up upgrade
service keys

Oncothyreon Inc.© quotemedia

Company Profile

Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in two phase III clinical trials for the treatment of non-small cell lung cancer. The company is also developing PX-866, a small molecule that is in phase II trials for various cancer indications. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine; and ONT-701, a pan-inhibitor of the B-cell lymphoma-2 family of anti-apoptotic proteins. The company operates primarily in the United States and Canada. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Recent News: Oncothyreon Inc.